Organization
Genecast Biotechnology Co., Ltd, Wuxi, China
2 abstracts
Abstract
Circulating tumor DNA as a predictor of treatment response to neoadjuvant chemotherapy in stage 2/3 rectal cancer without high risks: Subset analysis from the COPEC trial.Org: Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University; Department of General Surgery Depart.2 (Colorectal Gastrointestinal Surgery), West China Tianfu Hospital, Sichuan University, Chengdu, China, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China, Department of Radiology, West China Hospital, Sichuan University, Chengdu, China, Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, China, Genecast Biotechnology Co., Ltd., Wuxi, China,
Abstract
Dynamic ctDNA to inform the precise management of resected NSCLC: LUNGCA-2 study.Org: Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China, Department of Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Genecast Biotechnology Co., Ltd, Wuxi, China, Department of Thoracic surgery,Sichuan Provincial People's Hospital, Chengdu, China, Department of Thoracic Surgery, Chengdu Shangjinnanfu Hospital, Chengdu, China,